152 related articles for article (PubMed ID: 12858220)
1. Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
Gopcsa L; Barta A; Bányai A; Dolgos J; Halm G; Pálóczi K
Pathol Oncol Res; 2003; 9(2):131-3. PubMed ID: 12858220
[TBL] [Abstract][Full Text] [Related]
2. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
[TBL] [Abstract][Full Text] [Related]
4. Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
Bashey A; Shepherd S; Frankel W; Wang-Rodriguez J; Cahill T; Chamberlain M; Mason JR; Ho AD; Corringham RE
Oncol Rep; 1998; 5(1):281-5. PubMed ID: 9458334
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
[TBL] [Abstract][Full Text] [Related]
9. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P
Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Wang Y; Wu D; Sun A; Jin Z; Qiu H; Miao M; Tang X; Fu Z
Int J Hematol; 2008 Mar; 87(2):167-171. PubMed ID: 18288566
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
Tachibana T; Numata A; Tanaka M; Motohashi K; Fujisawa S; Fujita H; Sakai R; Tomita N; Maruta A; Ishigatsubo Y; Kanamori H
Leuk Lymphoma; 2011 Jul; 52(7):1376-9. PubMed ID: 21438838
[No Abstract] [Full Text] [Related]
12. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
13. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
Angstreich GR; Smith BD; Jones RJ
Curr Opin Oncol; 2004 Mar; 16(2):95-9. PubMed ID: 15075898
[TBL] [Abstract][Full Text] [Related]
14. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Bacigalupo A
Leukemia; 2003 Sep; 17(9):1722. PubMed ID: 12970770
[No Abstract] [Full Text] [Related]
15. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
16. Ph-negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph-positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate.
Skalska-Sadowska J; Januszkiewicz-Lewandowska D; Derwich K; Pieczonka A; Samborska M; Wachowiak J
Pediatr Blood Cancer; 2015 Jun; 62(6):1070-1. PubMed ID: 25631405
[TBL] [Abstract][Full Text] [Related]
17. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Jabbour E; Kantarjian H; O'Brien S; Rios MB; Abruzzo L; Verstovsek S; Garcia-Manero G; Cortes J
Blood; 2006 Jan; 107(2):480-2. PubMed ID: 16195326
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
19. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure.
O'Connor LM; Langabeer S; McCann SR; Conneally E
Bone Marrow Transplant; 2008 Dec; 42(12):833-5. PubMed ID: 18711344
[No Abstract] [Full Text] [Related]
20. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]